EBI EXPONENTIAL BIOTHERAPIES
Live / Registered — Registered (as of 29 Mar 2022)
What this means for you
Registered since 29 Mar 2022. The owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 87765139
- Registration number
- 6681763
- Mark type
- Design + words
- Filed
- 22 Jan 2018
- Published for opposition
- 11 Jan 2022
- Registered
- 29 Mar 2022
- Attorney of record
- HOPE V. SHOVEIN
Goods and services
- Class 005 — Pharmaceuticals: medicines, namely, medicines for alleviating or treating vasculogenic disease, medicines for alleviating or treating hemodynamic instabilities, medicines for alleviating or treating diabetes, medicines for alleviating or treating of immune system related diseases and disorders; pharmaceutical drugs, namely, pharmaceutical preparations for alleviating or treating vasculogenic disease, pharmaceutical preparations alleviating or treating hemodynamic instabilities, pharmaceutical preparations for alleviating or treating diabetes, pharmaceutical preparations for alleviating or treating of immune system related diseases and disorders; biopharmaceutical drugs, namely, biopharmaceutical preparations for alleviating or treating vasculogenic disease, biopharmaceutical preparations for alleviating or treating hemodynamic instabilities, biopharmaceutical preparations for alleviating or treating diabetes, biopharmaceutical preparations for alleviating or treating of immune system related diseases and disorders; biopharmaceuticals, namely, biopharmaceuticals for alleviating or treating vasculogenic disease, biopharmaceuticals alleviating or treating hemodynamic instabilities, biopharmaceuticals for alleviating or treating diabetes, biopharmaceuticals for alleviating or treating of immune system related diseases and disorders; synthetic peptides for biopharmaceutical purposes and for pharmaceutical purposes, namely, synthetic peptides for alleviating or treating vasculogenic disease, synthetic peptides for alleviating or treating hemodynamic instabilities, synthetic peptides for alleviating or treating diabetes, synthetic peptides for alleviating or treating of immune system related diseases and disorders; synthetic peptidemimetics for biopharmaceutical purposes and for pharmaceutical purposes, namely, sytnthetic peptidomimetics for alleviating or treating vasculogenic disease, synthetic peptidomimetics for alleviating or treating hemodynamic instabilities, synthetic peptidomimetics for alleviating or treating diabetes, synthetic peptidomimetics for alleviating or treating of immune system related diseases and disorders
- Class 040 — Treatment of materials: custom manufacture of medicines, pharmaceutical drugs, biopharmaceutical drugs, pharmaceuticals and biopharmaceuticals; treatment of biopharmaceutical and pharmaceutical materials being medicines, biopharmaceutical and pharmaceutical compounds, synthetic peptides and synthetic peptidomimetics; processing of medicines, biopharmaceutical and pharmaceutical compounds, synthetic peptides and synthetic peptidomimetics for others; custom manufacture of medical devices for others
- Class 042 — Scientific and technological services: biopharmaceutical and pharmaceutical research; conducting clinical trials for others in the fields of medicines, synthetic peptides and synthetic peptidomimetics as they relate to use as an ingredient in medicines, biopharmaceuticals, pharmaceuticals, pharmaceutical drugs and biopharmaceutical drugs; scientific research of medicines, synthetic peptides and synthetic peptidomimetics as they relate to use as an ingredient in medicines, biopharmaceuticals and pharmaceuticals, pharmaceutical drugs and biopharmaceutical drugs; development, testing, and inspection of medicines, synthetic peptides and synthetic peptidomimetics as they relate to use as an ingredient in medicines, pharmaceutical drugs, biopharmaceutical drugs, pharmaceuticals and biopharmaceuticals; laboratory services relating to medicines, synthetic peptides, synthetic peptidomimetics, pharmaceutical drugs, biopharmaceutical drugs, pharmaceuticals and biopharmaceuticals, namely, research in the fields of medicines, synthetic peptides, synthetic peptidomimetics, biopharmaceuticals, pharmaceuticals, pharmaceutical drugs and biopharmaceutical drugs; laboratory analysis in the fields of medicines, synthetic peptides, synthetic peptidomimetics, biopharmaceuticals, pharmaceuticals, pharmaceutical drugs and biopharmaceutical drugs; medical research in the fields of medicines, synthetic peptides, synthetic peptidomimetics, biopharmaceuticals, pharmaceuticals, pharmaceutical drugs and biopharmaceutical drugs; scientific research for medical purposes in the fields of medicines, synthetic peptides, synthetic peptidomimetics, biopharmaceuticals, pharmaceuticals, pharmaceutical drugs and biopharmaceutical drugs
Owner
- Exponential Biotherapies, Inc., New York, NY, US
- Exponential Biotherapies, Inc., New York, NY, US
- Exponential Biotherapies, Inc., New York, NY, US
Prosecution history
- 29 Mar 2022 — REGISTERED-PRINCIPAL REGISTER
- 11 Jan 2022 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 11 Jan 2022 — PUBLISHED FOR OPPOSITION
- 22 Dec 2021 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
- 07 Dec 2021 — LAW OFFICE PUBLICATION REVIEW COMPLETED
- 02 Dec 2021 — APPROVED FOR PUB - PRINCIPAL REGISTER
- 02 Dec 2021 — EXAMINER'S AMENDMENT ENTERED
- 02 Dec 2021 — NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
- 02 Dec 2021 — EXAMINERS AMENDMENT E-MAILED
- 02 Dec 2021 — EXAMINERS AMENDMENT -WRITTEN
- 29 Nov 2021 — PREVIOUS ALLOWANCE COUNT WITHDRAWN
- 09 Nov 2021 — WITHDRAWN FROM PUB - OG REVIEW QUERY
- 25 Oct 2021 — LAW OFFICE PUBLICATION REVIEW COMPLETED
- 16 Oct 2021 — APPROVED FOR PUB - PRINCIPAL REGISTER
- 13 Oct 2021 — TEAS/EMAIL CORRESPONDENCE ENTERED